Products Categories
CAS No.: | 3570-75-0 |
---|---|
Name: | Nifurthiazole |
Molecular Structure: | |
Formula: | C8H6 N4 O4 S |
Molecular Weight: | 254.226 |
Synonyms: | Formicacid, 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide (7CI,8CI);Hydrazinecarboxaldehyde, 2-[4-(5-nitro-2-furanyl)-2-thiazolyl]- (9CI);2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole; AS 17665; FNT; NSC 525334;Nifurthiazol; Nifurthiazole |
Density: | 1.612g/cm3 |
Melting Point: | 215.5°C (rough estimate) |
Boiling Point: | 454.8°Cat760mmHg |
Flash Point: | 228.9°C |
Safety: | Confirmed carcinogen with experimental carcinogenic and neoplastigenic data. Mutation data reported. When heated to decomposition it emits very toxic fumes of NOx and SOx. |
PSA: | 141.22000 |
LogP: | 3.00720 |
IUPAC Name: N-[[4-(5-Nitrofuran-2-yl)-1,3-thiazol-2-yl]amino]formamide
Synonyms of Nifurthiazole (CAS NO.3570-75-0) : 2-(4-(5-Nitro-2-furanyl)-2-thiazolyl)hydrazinecarboxaldehyde ; N'-[4-(5-Nitro-2-furyl)-1,3-thiazol-2-yl]formic hydrazide ; N'-[4-(5-nitrofuran-2-yl)-1,3-thiazol-2-yl]formic hydrazide ;nefurthiazole ; Thiazole, 2-(2-formylhydrazinyl)-4-(5-nitro-2-furanyl)-
InChI:InChI=1/C8H6N4O4S/c13-4-9-11-8-10-5(3-17-8)6-1-2-7(16-6)12(14)15/h1-4H,(H,9,13)(H,10,11)
CAS NO:3570-75-0
Molecular Formula:C8H6N4O4S
Molecular Weight :254.2226
Molecular Structure :
Index of Refraction: 1.679
Surface Tension: 74.4 dyne/cm
Density: 1.612 g/cm3
Flash Point: 228.9 °C
Enthalpy of Vaporization: 71.45 kJ/mol
Boiling Point: 454.8 °C at 760 mmHg
Vapour Pressure: 1.84E-08 mmHg at 25°C
Nifurthiazole (CAS NO.3570-75-0) is antimicrobial.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 445mg/kg (445mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Antimicrobial Agents and Chemotherapy Vol. -, Pg. 268, 1962. |
mouse | LD50 | oral | 1400mg/kg (1400mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | Antimicrobial Agents and Chemotherapy Vol. -, Pg. 268, 1962. |
IARC Cancer Review: Group 2B IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 ,1987,p. 56.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 ,1974,p. 151.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . EPA Genetic Toxicology Program.
Confirmed carcinogen with experimental carcinogenic and neoplastigenic data. Mutation data reported. When Nifurthiazole (CAS NO.3570-75-0) is heated to decomposition, it emits very toxic fumes of NOx and SOx.